AXL drives the aggressiveness of tumors by affecting stemness,migration, invasion, and epithelial-to-mesenchymal transition (EMT),while MER affects immunogenic signals in the tumor microenvironmentthrough efferocytosis and production of cytokines that impinge onthe tumor milieu.10 Thus, therapeutic MERand AXL inhibition would reverse treatment resistance, reduce tumorcell survival and metastatic capacity, and, at the same time, createa more robust antitumor immune response. Here, AXL is linked to neoplasm.